Correction to “Efficacy and Safety of Glucagon‐Like Peptide‐1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review”

Key Points

• This correction addresses findings on the efficacy of glucagon-like peptide-1 receptor agonists in obesity management.
• The systematic review reveals insights specifically for adults with and without type 2 diabetes.
• The analysis highlights the importance of these medications in treating obesity, emphasizing safety and effectiveness.
• Clarifying data may enhance understanding of efficacy in diverse patient populations, informing clinical practice.

Abstract